15. Q&A with Experts - Parts 1 & 2 - 2026 NCF Patient Conference
Special thanks to Josh Mailman for moderating these Q&A sessions. In these live Q&A sessions from the Neuroendocrine Cancer Foundation’s 2026 Virtual Annual Patient Conference, leading neuroendocrine cancer experts answer audience questions about diagnosis, treatment, imaging, symptoms, clinical trials, supportive care, and quality of life. The sessions feature Drs. Jennifer Chan, Chandrikha Chandrasekharan, Delphine Chen, Jaydira Del Rivero, Udhayvir Grewal, Thor Halfdanarson, Pamela Kunz, Michael Soulen, and Jason Starr, along with patient advocate and co-moderators Josh Mailman, and Lisa Yen. Topics include whether NETs are considered cancer, carcinoid syndrome, hormone-related symptoms, diet and tryptophan, bone pain and imaging, proton pump inhibitors and gastric NETs, somatostatin analogs, supplements, ivermectin, multidisciplinary care, unknown primary tumors, Dotatate PET scans, fertility, PRRT timing, palliative care, clinical trials, liver-directed therapy, histotripsy, GLP-1 medications, recurrence after surgery, and treatment decision-making. This discussion is designed to help patients, caregivers, and advocates better understand the complexity of neuroendocrine cancer care and the importance of expert guidance, patient education, shared decision-making, and support. Learn more about the Neuroendocrine Cancer Foundation and access patient resources at www.NCF.net.
Special thanks to Josh Mailman for moderating these Q&A sessions. In these live Q&A sessions from the Neuroendocrine Cancer Foundation’s 2026 Virtual Annual Patient Conference, leading neuroendocrine cancer experts answer audience questions about diagnosis, treatment, imaging, symptoms, clinical trials, supportive care, and quality of life. The sessions feature Drs. Jennifer Chan, Chandrikha Chandrasekharan, Delphine Chen, Jaydira Del Rivero, Udhayvir Grewal, Thor Halfdanarson, Pamela Kunz, Michael Soulen, and Jason Starr, along with patient advocate and co-moderators Josh Mailman, and Lisa Yen. Topics include whether NETs are considered cancer, carcinoid syndrome, hormone-related symptoms, diet and tryptophan, bone pain and imaging, proton pump inhibitors and gastric NETs, somatostatin analogs, supplements, ivermectin, multidisciplinary care, unknown primary tumors, Dotatate PET scans, fertility, PRRT timing, palliative care, clinical trials, liver-directed therapy, histotripsy, GLP-1 medications, recurrence after surgery, and treatment decision-making. This discussion is designed to help patients, caregivers, and advocates better understand the complexity of neuroendocrine cancer care and the importance of expert guidance, patient education, shared decision-making, and support. Learn more about the Neuroendocrine Cancer Foundation and access patient resources at www.NCF.net.